The US biopharmaceutical industry faces mounting global competition from countries in the developing world and Europe that are increasingly implementing pro-innovation programs and strategies in the sector, according to a new report conducted for the Pharmaceutical Research and Manufacturers of America (PhRMA)
The US biopharmaceutical industry faces mounting global competition from countries in the developing world and Europe that are increasingly implementing pro-innovation programs and strategies in the sector, according to a new report conducted for the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents leading US biopharmaceutical research companies. The report, Closing the Gap: Increasing Global Competition to Attract and Grow the Biopharmaceutical Sector, examines the efforts of 18 so-called “benchmark nations” in pursuing economic growth opportunities from the biopharmaceutical sector. The report seeks to remind US industry and policy leaders that US global leadership in biopharmaceutical research and development (R&D) can no longer be taken for granted.
The report’s authors warn that, like other R&D-intensive industries, the US biopharmaceutical industry faces more aggresive and globalized competition that seeks to challenge the United States’ global leadership in innovation. “The United States is now facing increasing competition to attract and grow a biopharmaceutical presence not just from developed countries, but also from emerging nations such as Brazil, China, and Singapore, that are laying the groundwork for future growth,” the report concludes. Many of the countries named are borrowing effective pro-innovation practices that have worked in the United States, and are building on them at the same time that the United States is, in some respects, becoming less favorable to innovation.
“Countries outside the United States are continuing to implement new ways to seek to grow their life sciences and biopharmaceutical presence as part of their economic development strategies,” the report notes. These nations have publicly funded infrastructure investments that are specifically designed to create a competitive advantage and to make those nations more attractive to biopharmaceutical industry investments.
The report identifies countries that are increasingly focused on building their biomedical R&D and manufacturing infrastructure—with a heavy focus on growing STEM workforces—so that they can better compete with the United States and lure critical investments. Singapore and China, for example, still outpace the United States in key STEM indicators—a sobering fact given current estimates suggesting that, by 2025, US manufacturers will need to hire about 3.4 million workers, with up to 60% of positions likely to go unfilled because of STEM skills gaps in the United States.
The United States must ensure that the right policies are in place to retain its global leadership position and seize the potential for continued economic growth, the report counsels. Three areas of intensive recent activity include:
Other policy areas of ongoing focus in benchmark nations include accelerating the commercialization of university research and new firm formation, increasing access to investment capital, fostering industry R&D investment via tax and other incentives, and building human capital. Benchmark nations have increased their levels of government-supported research funding, whereas the United States has decreased such funding. Similarly, US spending on R&D is growing at a much slower rate than that of other nations examined. US patent growth lags behind that of other nations, with China more than doubling the size of its patent activity and closing in on the United States in absolute number of patents awarded.
Anne Pritchett, PhD, Vice President of Policy and Research at PhRMA, said, “As we look to the future, our nation’s innovative biopharmaceutical companies are committed to partnering with schools of all levels across the country to develop the next generation of scientists, engineers and technicians who are critical to advancing new treatments and cures.” Continued support of STEM-based initiatives and educational opportunities will make it possible for America to continue to grow the economy, an economy that today, as Pritchett noted, includes 4.5 million jobs supported by the biopharmaceutical industry.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.